Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus b conjugate vaccine (Novartis)
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A monovalent conjugate vaccine used for the prevention of invasive diseases caused by *Haemophilus influenzae* type b (Hib), such as meningitis, pneumonia, and epiglottitis. The vaccine consists of the Hib capsular polysaccharide, polyribosylribitol phosphate (PRP), which is chemically conjugated to a carrier protein (such as CRM197 in the case of Vaxem Hib) to enhance its immunogenicity, particularly in infants and young children. This conjugation process converts the polysaccharide from a T-cell independent to a T-cell dependent antigen, allowing for the induction of immunological memory and a more robust antibody response. Originally developed by companies like Novartis (Vaxem Hib), these vaccines are now standard components of pediatric immunization schedules worldwide.
- Brand names
- Vaxem HibActHIBHiberixPedvaxHIB
- Other names
- Haemophilus influenzae type b vaccineHib vaccinePRP-TPRP-OMPPRP-CRM
Beyond the preview
Go deeper on haemophilus b conjugate vaccine (Novartis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus b conjugate vaccine (Novartis).